Chronic subdural haematoma: modern management and emerging therapies
Chronic subdural haematoma (CSDH) is one of the most common neurological disorders,
and is especially prevalent among elderly individuals. Surgical evacuation is the mainstay of …
and is especially prevalent among elderly individuals. Surgical evacuation is the mainstay of …
Cryo-EM in drug discovery: achievements, limitations and prospects
JP Renaud, A Chari, C Ciferri, W Liu… - Nature reviews Drug …, 2018 - nature.com
Cryo-electron microscopy (cryo-EM) of non-crystalline single particles is a biophysical
technique that can be used to determine the structure of biological macromolecules and …
technique that can be used to determine the structure of biological macromolecules and …
Efficient networks for quantum factoring
D Beckman, AN Chari, S Devabhaktuni, J Preskill - Physical Review A, 1996 - APS
We consider how to optimize memory use and computation time in operating a quantum
computer. In particular, we estimate the number of memory quantum bits (qubits) and the …
computer. In particular, we estimate the number of memory quantum bits (qubits) and the …
[HTML][HTML] B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
N Shah, A Chari, E Scott, K Mezzi, SZ Usmani - Leukemia, 2020 - nature.com
Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade,
a substantial proportion of patients do not respond to current therapies or have a short …
a substantial proportion of patients do not respond to current therapies or have a short …
[HTML][HTML] Teclistamab in relapsed or refractory multiple myeloma
…, AK Nooka, T Martin, L Rosinol, A Chari… - … England Journal of …, 2022 - Mass Medical Soc
Background Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of …
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of …
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Background New treatment options are needed for patients with multiple myeloma that is
refractory to proteasome inhibitors and immunomodulatory drugs. We assessed daratumumab, …
refractory to proteasome inhibitors and immunomodulatory drugs. We assessed daratumumab, …
[PDF][PDF] Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy
…, CC Hofmeister, YA Efebera, S Jagannath, A Chari… - Cancer cell, 2014 - cell.com
We performed massively parallel sequencing of paired tumor/normal samples from 203
multiple myeloma (MM) patients and identified significantly mutated genes and copy number …
multiple myeloma (MM) patients and identified significantly mutated genes and copy number …
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
…, B Reeves, C Rodriguez, A Chari… - Blood, The Journal …, 2020 - ashpublications.org
Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell
transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with newly …
transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with newly …
[HTML][HTML] Oral selinexor–dexamethasone for triple-class refractory multiple myeloma
A Chari, DT Vogl, M Gavriatopoulou… - … England Journal of …, 2019 - Mass Medical Soc
Background Selinexor, a selective inhibitor of nuclear export compound that blocks exportin
1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, …
1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, …
Atomic-resolution protein structure determination by cryo-EM
Single-particle electron cryo-microscopy (cryo-EM) is a powerful method for solving the three-dimensional
structures of biological macromolecules. The technological development of …
structures of biological macromolecules. The technological development of …